<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405388</url>
  </required_header>
  <id_info>
    <org_study_id>30-468 ex 17/18</org_study_id>
    <nct_id>NCT04405388</nct_id>
  </id_info>
  <brief_title>Spermidine Anti-Hypertension Study</brief_title>
  <acronym>SMARTEST</acronym>
  <official_title>Spermidine Anti-Hypertension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ETH Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The impact of daily spermidine application on arterial blood pressure and other secondary
      parameters will be evaluated in a double-blind single center 46 patients cross-over study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arterial hypertension is a central risk factor for cardiovascular disease, major
      cardiovascular events and mortality. Treatment of arterial hypertension necessitates
      lifestyle modifications, but often also requires medical intervention. In most cases, a
      combination of two or more anti-hypertensive drugs is recommended and necessary for reaching
      the target blood pressure levels.

      Hypotheses / research questions/objectives Spermidine potentiates the blood pressure lowering
      effect of standard anti-hypertensive medications, particularly when a combination of at least
      two first-line drugs (as recommended by the European Society of Cardiology guidelines) has
      not resulted in sufficient and adequate blood pressure control.

      Approach/methods Spermidine Anti-Hypertension Study (SMARTEST) is a prospective, randomized
      and double-blind placebo-controlled single-centre trial with a balanced 2x2 crossover design,
      where 46 medically pre-treated hypertensive patients will be subsequently treated with
      spermidine and placebo (each for eight weeks) in two arms of opposite treatment sequence. A
      washout period of four weeks will separate the two intervention periods in both arms.

      Patients will undergo physical examination, ECG (electrocardiogram), echocardiography, and
      blood draws at four time points coinciding with the baseline and termination of each
      treatment at: 0, 8, 12, and 20 weeks of/after recruitment at the Department of Cardiology,
      Medical University of Graz. In addition, 24-hour ambulatory blood pressure (24-h BP)
      monitoring (BPM; Mobil-O-Graph®) and on-site blood pressure will be obtained (the device will
      be sent back to the hospital the following day) at these time points. A 6-minute walk test
      (6MWT) will be performed at every visit.

      Spermidine will be administered orally as an approved dietary supplement (spermidine-rich
      wheat germ extract) at a dose of 4 mg spermidine per day for eight weeks. The primary outcome
      will be arterial systolic blood pressure at 24h BPM. Further secondary outcomes/safety
      outcomes will be:

      24-h BP: analysis of systolic, diastolic and mean arterial blood pressures and pulse wave
      analysis; on site ambulatory blood pressure; 6 minute walk test distance (difference in
      meters); laboratory analysis; ECG - standard parameters; Echocardiography: standard
      parameters as well as strain analysis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure in an ambulatory 24h blood pressure measurement</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Patients will get RR recordings in an ambulatory setting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>recorded with the Mobil-O-Graph® PWA, I.E.M. GmbH, Stolberg, Germany</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>recorded with the Mobil-O-Graph® PWA, I.E.M. GmbH, Stolberg, Germany</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean blood pressure</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>recorded with the Mobil-O-Graph® PWA, I.E.M. GmbH, Stolberg, Germany</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central blood pressure</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>recorded with the Mobil-O-Graph® PWA, I.E.M. GmbH, Stolberg, Germany</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>tested at every visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Spermidine first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First treatment period (8 weeks) will be 4 mg spermidine per day orally. Afterwards 4 weeks of wash-out followed by 8 weeks of placebo treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First treatment period (8 weeks) will be placebo. Afterwards 4 weeks of wash-out followed by 8 weeks of 4 mg spermidine per day orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given orally as capsule (same size and weight as Spermidine capula)</description>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_label>Spermidine first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spermidine</intervention_name>
    <description>Spermidine will be given orally as capsule (4mg/day)</description>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_label>Spermidine first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide signed and dated informed consent form

          -  Persistant arterial hypertension with systolic blood pressure above 150 mmHg during
             hospitalisation and the day of randomisation

          -  Stable anti-hypertensive medication with at least two guideline-recommended
             anti-hypertensive drugs

        Exclusion Criteria:

          -  Systolic blood pressure ≥180mmHg on the day of randomisation

          -  Spermidine intolerance

          -  Significant renal impairment defined as glomerular filtration rate &lt; 45ml/min

          -  Insulin-dependent diabetes mellitus (IDDM)

          -  Wheat allergy or gluten intolerance

          -  Life expectancy of less than 12 months

          -  Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk von Lewinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Sedej, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Eisenberg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Graz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmoud Abdellatif, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk von Lewinski, MD</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>80684</phone_ext>
    <email>dirk.von-lewinski@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markus Wallner, MD</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>31262</phone_ext>
    <email>markus.wallner@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk von Lewinski</last_name>
      <phone>+4331638580684</phone>
      <email>dirk.von-lewinski@medunigraz.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>Eisenberg T, Abdellatif M, Schroeder S, Primessnig U, Stekovic S, Pendl T, Harger A, Schipke J, Zimmermann A, Schmidt A, Tong M, Ruckenstuhl C, Dammbrueck C, Gross AS, Herbst V, Magnes C, Trausinger G, Narath S, Meinitzer A, Hu Z, Kirsch A, Eller K, Carmona-Gutierrez D, Büttner S, Pietrocola F, Knittelfelder O, Schrepfer E, Rockenfeller P, Simonini C, Rahn A, Horsch M, Moreth K, Beckers J, Fuchs H, Gailus-Durner V, Neff F, Janik D, Rathkolb B, Rozman J, de Angelis MH, Moustafa T, Haemmerle G, Mayr M, Willeit P, von Frieling-Salewsky M, Pieske B, Scorrano L, Pieber T, Pechlaner R, Willeit J, Sigrist SJ, Linke WA, Mühlfeld C, Sadoshima J, Dengjel J, Kiechl S, Kroemer G, Sedej S, Madeo F. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med. 2016 Dec;22(12):1428-1438. doi: 10.1038/nm.4222. Epub 2016 Nov 14.</citation>
    <PMID>27841876</PMID>
  </results_reference>
  <results_reference>
    <citation>Wirth M, Benson G, Schwarz C, Köbe T, Grittner U, Schmitz D, Sigrist SJ, Bohlken J, Stekovic S, Madeo F, Flöel A. The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial. Cortex. 2018 Dec;109:181-188. doi: 10.1016/j.cortex.2018.09.014. Epub 2018 Oct 4.</citation>
    <PMID>30388439</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>May 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>individual data will only be shared after approval of the local EC</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT04405388/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

